Phase II Study of Hypofractionated Intensity Modulated Radiation Therapy (IMRT) With Incorporated Boost in Early Stage Breast Cancer
- Determine the toxicity associated with adjuvant hypofractionated intensity-modulated
radiotherapy using an incorporated boost in patients with early-stage breast cancer.
- Determine the long-term cosmetic result and quality of life of patients treated with
- Determine the long-term local control in patients treated with this regimen.
OUTLINE: Patients undergo adjuvant hypofractionated intensity-modulated radiotherapy with
incorporated boost once daily 5 days a week for 4 weeks.
Quality of life is assessed within 1 month of starting radiotherapy, at 6 weeks after
completion of radiotherapy, and then every 6 months for 5 years.
Patients are followed at 6 weeks and then every six months for 5 years.
PROJECTED ACCRUAL: A total of 37-74 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Acute toxicity by CTCAE at 6 weeks
Penny Anderson, MD
Fox Chase Cancer Center
United States: Federal Government
|Fox Chase Cancer Center||Philadelphia, Pennsylvania 19111|